Mike Montemarano, Associate Editor 03.29.21
Probi, a Swedish probiotic supplier, and Sinopharm, one of China’s largest pharmaceutical and healthcare companies, have entered a partnership to offer probiotic supplements to the Chinese marketplace. Sinopharm will launch three probiotic supplements formulated to benefit immune health, bone health, and iron absorption, respectively, based on Probi’s clinically-substantiated probiotic strains.
“Sinopharm continues to commit to our strong sense of social responsibility of ‘caring for life, attending to health,’” Zhang Jian Ge, director of Sinopharm’s Pharmaceutical and Chemical Division, said. “Guided by our core value ‘all for health, health for all,’ Sinopharm’s recent strategic partnership with Probi, especially its best-in-class R&D capability, helps us contribute with positive impact to China’s consumer healthcare industry. The products have clinically documented positive effects and will be introduced under a new brand to expand Sinopharm’s existing supplement portfolio.”
Probiotic supplements are a high-growth segment in China, and, citing market research company Euromonitor, are expected to experience a growth rate of 10.3% CAGR over the next five years, Probi said.
“We are excited to partner with Sinopharm, who shares our vision of bringing innovative and scientifically supported products into China and the APAC [Asia Pacific] region,” Veronica Dong, head of Probi’s APAC division, said. “With this partnership, Probi ahs demonstrated its position as a leading probiotic company to capture high-growth markets in the region such as China.”
“The partnership between Probi and Sinopharm is an important step in our commercial efforts in offering clinically documented probiotic products to consumers all over the world, and our expansion into China is a good step forward in establishing Probi’s position in the APAC region,” Tom Rönnlund, CEO of Probi, said. “In our partnership with Sinopharm we feel commitment and alignment in offering high quality products based upon research, clinical documentation, and performance.”
Mike Montemarano has been the Associate Editor of Nutraceuticals World since February 2020. He can be reached at mmontemarano@rodmanmedia.com.
“Sinopharm continues to commit to our strong sense of social responsibility of ‘caring for life, attending to health,’” Zhang Jian Ge, director of Sinopharm’s Pharmaceutical and Chemical Division, said. “Guided by our core value ‘all for health, health for all,’ Sinopharm’s recent strategic partnership with Probi, especially its best-in-class R&D capability, helps us contribute with positive impact to China’s consumer healthcare industry. The products have clinically documented positive effects and will be introduced under a new brand to expand Sinopharm’s existing supplement portfolio.”
Probiotic supplements are a high-growth segment in China, and, citing market research company Euromonitor, are expected to experience a growth rate of 10.3% CAGR over the next five years, Probi said.
“We are excited to partner with Sinopharm, who shares our vision of bringing innovative and scientifically supported products into China and the APAC [Asia Pacific] region,” Veronica Dong, head of Probi’s APAC division, said. “With this partnership, Probi ahs demonstrated its position as a leading probiotic company to capture high-growth markets in the region such as China.”
“The partnership between Probi and Sinopharm is an important step in our commercial efforts in offering clinically documented probiotic products to consumers all over the world, and our expansion into China is a good step forward in establishing Probi’s position in the APAC region,” Tom Rönnlund, CEO of Probi, said. “In our partnership with Sinopharm we feel commitment and alignment in offering high quality products based upon research, clinical documentation, and performance.”
Mike Montemarano has been the Associate Editor of Nutraceuticals World since February 2020. He can be reached at mmontemarano@rodmanmedia.com.
